Methods of treatment using a gastric retained gabapentin dosage
Granted: October 21, 2008
Patent Number:
7438927
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Methods of treatment using a gastric retained losartan dosage
Granted: August 19, 2008
Patent Number:
7413751
A method of treatment for hypertension and other disease states is described, which comprises the delivery of losartan in a gastric retained dosage form.
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
Granted: July 29, 2008
Patent Number:
7405238
Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon…
Optimal polymer mixtures for gastric retentive tablets
Granted: April 20, 2004
Patent Number:
6723340
Unit dosage form tablets for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the tablet to effect gastric retention and gradual disintegration of the tablet to clear the tablet from the gastrointestinal tract after release…
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
Granted: January 27, 2004
Patent Number:
6682759
A method is disclosed for manufacturing a pharmaceutical tablet for oral administration, the tablet combining both immediate-release and prolonged-release modes of drug delivery and using an immediate-release drug that is either insoluble in water or only sparingly soluble and is present in a very small amount compared to the prolonged-release drug. The method involves the use of particles of the immediate-release drug that are equal to or less than 10 microns in diameter, applied as a…
Extending the duration of drug release within the stomach during the fed mode
Granted: October 21, 2003
Patent Number:
6635280
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution…
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Granted: December 3, 2002
Patent Number:
6488962
The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent…
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
Granted: September 17, 2002
Patent Number:
6451808
Metformin is formulated as a pharmaceutical composition that also includes a 5-hydroxytryptamine-3 receptor antagonist to suppress the gastrointestinal side effects that are associated with metformin administration in many patients.
Extending the duration of drug release within the stomach during the fed mode
Granted: January 22, 2002
Patent Number:
6340475
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution…
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
Granted: October 26, 1999
Patent Number:
5972389
Controlled-release oral drug dosage forms that comprise a tablet or capsule containing a plurality of particles of a solid-state drug dispersed in a swellable/erodible polymer, such as poly(ethylene oxide) are described. Once ingested, the tablet or capsule disintegrates to disperse the particles within the stomach where they imbibe water to cause them to swell and promote retention in fed-mode-induced patients. As the gastric-retained dosage form gradually erodes, the drug is released…
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
Granted: December 10, 1996
Patent Number:
5582837
Sustained release oral drug dosage forms that comprise a tablet or capsule containing a plurality of particles of a solid-state drug dispersed in alkyl cellulose such as hydroxyethylcellulose or hydroxypropylcellulose. Once ingested the tablet or capsule disintegrates to disperse the particles into the stomach where they imbibe water to cause them to swell and also to become slippery, thus enhancing their retention in the stomach. Imbibed water from the gastric fluid dissolves the drug…
Sustained-release oral drug dosage form
Granted: April 16, 1991
Patent Number:
5007790
Sustained-release oral drug-dosage forms that release drug in solution at a rate controlled by the solubility of the drug are described. The dosage form comprises a tablet or capsule which comprises a plurality of particles of a dispersion of a limited solubility drug in a hydrophilic, water-swellable, crosslinked polymer that maintains its physical integrity over the dosing lifetime but thereafter rapidly dissolves. Once ingested, the particles swell to promote gastric retention and…
